Antihyperlipidemic Drugs Market Size to Reach US$ 16.0 Billion by 2028 at 4.6% CAGR

IMARC Group, a leading market research company, has recently releases a report titled "Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028." The study provides a detailed analysis of the industry, including the global antihyperlipidemic drugs market report , share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

How Big is the Antihyperlipidemic Drugs Market?

The global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.0 Billion by 2028, exhibiting a growth rate (CAGR) of 4.6% during 2023-2028.

Request a PDF Sample for more detailed market insights: https://www.imarcgroup.com/antihyperlipidemic-drugs-market/requestsample

Antihyperlipidemic drugs are a class of medications specifically designed to reduce the levels of lipids or fats in the blood, particularly cholesterol and triglycerides. They function by two pathways, which involve lowering the cholesterol production of the liver or increasing the removal of cholesterol from the blood. They are available in various forms, including statins, nicotinic acid, bile acid sequestrants, and cholesterol absorption inhibitors. They aid in managing lipid levels and benefit overall health by promoting better blood circulation and reducing the risk of peripheral artery disease. They treat hyperlipidemia, a condition characterized by abnormally high levels of lipids in the blood. They are cost-effective as they reduce the need for costly treatments or surgeries related to untreated hyperlipidemia.

What are the growth prospects and trends in the antihyperlipidemic drugs industry?

At present, the rising geriatric population that is more susceptible to higher cholesterol levels and atherosclerosis represents one of the crucial factors impelling the market growth. Additionally, the increasing awareness about the dangers of high cholesterol levels and the benefit of early detection of hyperlipidemia is encouraging more people to take proactive measures to get their cholesterol levels tested for early diagnosis. Besides this, the growing trend of personalized therapies based on genetic and molecular profiling, which cater to individual patient needs, is offering a favorable market outlook.

Moreover, the rising implementation of campaigns and programs by governing agencies and health organizations to emphasize the significance of heart health and promote therapeutic interventions like antihyperlipidemic drugs is propelling the market growth. In addition, the increasing introduction of novel classes of antihyperlipidemic medications, such as PCSK9 inhibitors, especially for patients who are intolerant or resistant to traditional therapies, is bolstering the market growth.

Furthermore, the rising number of investments in research and development (R&D) activities by pharma companies is improving the efficacy and reducing the side effects of antihyperlipidemic agents. Apart from this, the increasing integration artificial intelligence (AI) and machine learning (ML) in drug discovery is enabling faster identification and development of potential antihyperlipidemic agents.

Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/antihyperlipidemic-drugs-market

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Drug Class:
• Statins
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• PCSK9 Inhibitors
• Combination
• Others

Breakup by Route of Administration:
• Oral
• Intravenous

Breakup by Distribution Channel:
• Hospital Pharmacies
• Retail Stores
• Online Retailers

Breakup by Region:
• North America: (United States, Canada)
• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America: (Brazil, Mexico, Others)
• Middle East and Africa

Some of the Top Key players in the Antihyperlipidemic Drugs Market

Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/

This release was published on openPR.